#Norway #Oslo #Radspherin #Nuclear Medicine #Oncoinvent

Oncoinvent's Radspherin® Clinical Dosimetry Results

On August 11, 2026, Oncoinvent, a pioneering biotech company, announced a significant milestone with the publication of clinical dosimetry results for Radspherin® in the Journal of Nuclear Medicine. This publication marks an important step in the development of receptor-independent alpha radiopharmaceuticals aimed at combating cancer cells in the abdominal cavity post-surgery.

The study centered around nine patients who participated in the dosimetry cohorts of the Phase 1 Radspherin® trials targeting ovarian and colorectal cancers. Notably, the data revealed that the radiation doses absorbed by normal organs were markedly below the levels typically associated with toxicity risks, thereby affirming the favorable safety profile that has been observed throughout these studies.

Caroline Stokke, the senior author of the publication and Head of Nuclear Medicine Physics at Oslo University Hospital, emphasized the significance of understanding radiation exposure in early-phase clinical studies. According to Stokke, dosimetry not only helps in assessing potential toxicity but also in identifying tissues that may limit dosing. She explained that the complexity of dosimetry procedures for alpha therapies often necessitates alternative methodologies, as imaging techniques might not directly apply. To overcome these challenges, a combination of blood sampling and biokinetic modeling was employed to accurately estimate radiation exposure in normal tissues.

Conducted at The Norwegian Radium Hospital, the dosimetry study focused on how radiation emitted from Radspherin® disseminates to surrounding healthy tissues after treatment. The results were promising: absorbed radiation doses to essential organs, including the kidneys and red bone marrow, remained well within safe limits. This finding was particularly vital, as unintended radiation exposure to healthy tissues is often a significant hurdle in the development of effective radiopharmaceutical therapies.

Kari Myren, Chief Medical Officer at Oncoinvent, expressed satisfaction about the published results, articulating gratitude for the collaborative efforts with Oslo University Hospital and the journey towards innovative cancer treatments. Myren noted that the previously established favorable safety profile in clinical trials and the data confirming low radiation exposure to healthy organs collectively support Radspherin®’s potential to offer hope to patients facing limited treatment options.

The research not only enhances the understanding of Radspherin®’s therapeutic potential but also reinforces the ongoing commitment to refining and advancing treatment modalities for patients battling challenging cancer types, specifically those with peritoneal metastases.

As Oncoinvent continues its trajectory of innovation in radiopharmaceuticals, this latest publication serves as a beacon of promise for the future of cancer therapies, where patient safety and treatment efficacy can ideally go hand in hand. Prospects for further development of Radspherin® are now more hopeful than ever, offering patients a glimmer of hope in an arena often met with limited options.

For any inquiries or further information regarding this study or Radspherin®, please reach out to Oystein Soug, CEO of Oncoinvent, or the communication team at Optimum Strategic Communications.